Lisinopril & Losartan Interaction

The concurrent use of lisinopril and losartan is classified as contraindicated due to the dangerous additive effects of dual renin-angiotensin-aldosterone system (RAAS) blockade ^[1][2]. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor, while losartan is an angiotensin II receptor blocker (ARB) — both drugs target the same hormonal pathway but at different points, and their combination provides no additional cardiovascular benefit while substantially increasing the risks of hyperkalemia, hypotension, and acute kidney injury ^[3][4]. The landmark ONTARGET trial definitively demonstrated that dual RAAS blockade with an ACE inhibitor plus ARB increased adverse events without improving outcomes ^[3].

Major clinical guidelines from the AHA, ACC, ESC, and KDIGO uniformly recommend against combining ACE inhibitors with ARBs for the treatment of hypertension, heart failure, or diabetic nephropathy ^[4][5][6]. The FDA has issued specific warnings about dual RAAS blockade, and the prescribing information for both drug classes explicitly advises against this combination ^[1][2]. Despite these warnings, inadvertent co-prescription continues to occur, often when patients see multiple providers who independently prescribe agents from each class ^[5].

Patients at highest risk for severe adverse outcomes include those with chronic kidney disease (particularly eGFR < 60 mL/min/1.73 m²), diabetes mellitus, heart failure, dehydration, advanced age, and concurrent use of potassium-sparing diuretics, potassium supplements, or NSAIDs ^[1][2][3]. In these populations, dual RAAS blockade can precipitate life-threatening hyperkalemia (potassium > 6.0 mEq/L) requiring emergency intervention ^[3][4].

The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that maintains blood pressure and fluid balance ^[1][2]. Renin cleaves angiotensinogen to angiotensin I, which ACE converts to angiotensin II. Angiotensin II acts on AT1 receptors to cause vasoconstriction, aldosterone secretion (promoting sodium and water retention), sympathetic activation, and cardiac remodeling ^[1][2]. Lisinopril blocks ACE, reducing angiotensin II production, while losartan blocks AT1 receptors, preventing angiotensin II from exerting its effects even if it is produced via alternative pathways (e.g., chymase) ^[1][2].

When both drugs are used together, the RAAS is suppressed at two levels simultaneously, producing excessive vasodilation and a disproportionate reduction in glomerular filtration pressure ^[3][4]. In the kidney, angiotensin II constricts the efferent arteriole to maintain glomerular filtration pressure. Dual RAAS blockade eliminates this compensatory mechanism, causing a precipitous decline in GFR, particularly in patients who are volume-depleted, have bilateral renal artery stenosis, or have pre-existing chronic kidney disease ^[3][6]. This manifests clinically as acute kidney injury with rising serum creatinine ^[3][4].

The hyperkalemia risk is also mechanistically additive. Angiotensin II stimulates aldosterone release, which promotes renal potassium excretion in the collecting duct. Both ACE inhibitors and ARBs reduce aldosterone levels, impairing potassium excretion ^[1][2]. Dual blockade produces a greater reduction in aldosterone than either agent alone, leading to potassium retention that can be severe and rapid in onset ^[3][4]. The combination also produces greater blood pressure reduction than either agent alone, increasing the risk of symptomatic hypotension, syncope, and falls — particularly in the elderly or volume-depleted patients ^[3][5].

The ONTARGET trial (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) randomized 25,620 patients to ramipril alone, telmisartan alone, or the combination ^[3]. The dual RAAS blockade group showed no reduction in the primary composite endpoint (cardiovascular death, MI, stroke, HF hospitalization) compared to monotherapy (HR 0.99, 95% CI 0.92–1.07), but experienced significantly more adverse events: hypotension (4.8% vs 1.7%, p < 0.001), syncope (0.3% vs 0.2%), renal impairment (13.5% vs 10.2%, p < 0.001), and hyperkalemia requiring discontinuation (0.3% vs 0.1%) ^[3][4].

The VA NEPHRON-D trial specifically evaluated dual RAAS blockade in diabetic nephropathy — a population where additive renal protection was theorized — and was stopped early due to safety concerns ^[4][7]. Patients receiving losartan plus lisinopril had a significantly higher rate of hyperkalemia (6.3 per 100 person-years vs 2.8, p < 0.001) and acute kidney injury (12.2% vs 6.7%, p < 0.001) compared to losartan alone, with no benefit in the primary endpoint of decline in eGFR, ESRD, or death ^[7]. These results definitively refuted the hypothesis that dual RAAS blockade provides additive renal protection ^[4][7].

Life-threatening hyperkalemia (potassium > 6.5 mEq/L) is the most dangerous acute consequence, capable of causing cardiac arrhythmias including ventricular fibrillation and asystole ^[3][4]. Symptomatic hypotension can lead to falls, fractures (particularly hip fractures in the elderly), and syncope-related injuries ^[3][5]. Acute kidney injury may progress to dialysis-requiring renal failure in severe cases, particularly in patients who are concurrently dehydrated from intercurrent illness, diuretic use, or hot weather ^[4][7].

The primary management recommendation is to discontinue one of the two agents ^[3][4][5]. There is no clinical scenario in which the combination of an ACE inhibitor and an ARB is recommended by current guidelines ^[4][5][6]. If a patient is discovered to be on both drugs, one should be stopped immediately after assessing which agent the patient has been on longer and tolerated better ^[5]. The remaining RAAS blocker should be continued at an adequate dose to achieve blood pressure and proteinuria targets ^[4][6].

If a patient is being transitioned from one class to the other (e.g., switching from lisinopril to losartan due to ACE inhibitor cough), a washout period of 24–48 hours is recommended, though same-day switching is acceptable in supervised settings with close monitoring ^[1][2]. During the transition, blood pressure should be monitored closely and potassium and creatinine checked within 1–2 weeks ^[1][2]. If the patient was on dual RAAS blockade inadvertently for an extended period, laboratory monitoring (potassium, creatinine, eGFR) should be performed immediately and repeated 1 week after discontinuing the second agent ^[3][4].

For patients with heart failure who need additional RAAS modulation beyond a single ACE inhibitor or ARB, sacubitril/valsartan (Entresto) — an angiotensin receptor-neprilysin inhibitor (ARNI) — is the guideline-directed alternative, but it must NOT be combined with an ACE inhibitor (allow a 36-hour washout) and is used instead of, not in addition to, an ARB ^[5][8]. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) provide complementary RAAS blockade with evidence-based mortality benefit in HFrEF and can be safely added to a single ACE inhibitor or ARB with potassium monitoring ^[5][8].

If a patient is found to be on both lisinopril and losartan, immediate laboratory assessment is required: serum potassium, serum creatinine, eGFR, and blood pressure ^[3][4]. Potassium > 5.5 mEq/L requires urgent management — potassium > 6.0 mEq/L with ECG changes (peaked T waves, widened QRS, loss of P waves) is a medical emergency requiring IV calcium gluconate, insulin/glucose, and potentially emergent dialysis ^[3][4]. After discontinuing one agent, repeat potassium and creatinine should be checked in 3–7 days and again at 1 month to ensure normalization ^[1][2].

For the remaining RAAS blocker, standard monitoring applies: potassium and creatinine at baseline, 1–2 weeks after initiation or dose change, and every 3–6 months during stable therapy ^[1][2][6]. Blood pressure should be assessed at each clinic visit, with a target of < 130/80 mmHg for most patients ^[5]. Patients should be educated about symptoms of hyperkalemia (muscle weakness, paresthesias, palpitations), hypotension (dizziness, lightheadedness on standing, syncope), and acute kidney injury (reduced urine output, edema, fatigue) ^[1][2].

Medication reconciliation is essential at every clinical encounter to prevent inadvertent reintroduction of dual RAAS blockade, particularly when patients transition between providers, are discharged from hospital, or are prescribed medications by specialists ^[5]. Electronic health record (EHR) drug interaction alerts should not be overridden for this combination. Pharmacists play a critical role in identifying and flagging this contraindicated combination during prescription review ^[4][5].

For patients requiring more intensive blood pressure control than a single RAAS blocker provides, guideline-recommended add-on therapies include calcium channel blockers (amlodipine being the most commonly combined), thiazide or thiazide-like diuretics (chlorthalidone, hydrochlorothiazide, indapamide), or both ^[5][8]. The ACCOMPLISH trial demonstrated that the combination of an ACE inhibitor plus amlodipine was superior to ACE inhibitor plus hydrochlorothiazide for cardiovascular outcomes, making ACE/CCB combinations an evidence-based choice ^[5]. For patients specifically needing renal protection in diabetic nephropathy, maximizing the dose of a single RAAS blocker (e.g., losartan 100 mg daily or lisinopril 40 mg daily) is preferred over adding a second RAAS blocker ^[6][7].

For heart failure with reduced ejection fraction (HFrEF), the guideline-directed medical therapy includes a single RAAS blocker (preferably sacubitril/valsartan as the ARNI, or an ACE inhibitor if ARNI is not tolerated), a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin) ^[5][8]. This four-pillar approach provides comprehensive neurohormonal blockade with established mortality benefits and does not require dual ACE inhibitor/ARB therapy ^[8].

If a patient has ACE inhibitor cough (a class effect occurring in 5–10% of patients due to bradykinin accumulation), switching to an ARB is the standard approach — they should not be combined ^[1][2]. For patients with angioedema from an ACE inhibitor (a rare but potentially life-threatening reaction), ARBs can be used with caution, as cross-reactivity is low (< 2%), though sacubitril/valsartan is contraindicated due to its effects on bradykinin metabolism ^[1][2][8].